Pedro Mezquita‐Raya

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero‐Gómez et al. · Journal of Clinical Medicine · 2022 · 292 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Relation Between Vitamin D Insufficiency, Bone Density, and Bone Metabolism in Healthy Postmenopausal Women

Pedro Mezquita‐Raya, Manuel Muñoz‐Torres, Juan de Dios Luna et al. · Journal of Bone and Mineral Research · 2001 · 214 citations · Full text

Medicine, Endocrinology, Nutritional Sciences +17

The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women

Pedro Mezquita‐Raya, Magdalena de la Higuera, Diego Fernández García et al. · Osteoporosis International · 2005 · 99 citations

Medicine, Endocrinology, Orthopedic Surgery +16

Performance of quantitative ultrasound in the discrimination of prevalent osteoporotic fractures in a bone metabolic unit

Fernando López Rodríguez, Pedro Mezquita‐Raya, Juan de Dios Luna et al. · Bone · 2003 · 43 citations

Medicine, Orthopedic Surgery, Radiology +16